Cytomx Therapeutics Inc SEC Filings

CytomX Therapeutics reported 2025 results showing a sharp revenue decline alongside progress in its oncology pipeline. Revenue was $76.2 million for 2025, down from $138.1 million in 2024, mainly due to completion and slower recognition of collaboration revenues. Total operating expenses fell to $98.6 million from $113.1 million, but the company moved from net income of $31.9 million in 2024 to a net loss of $17.4 million in 2025, or $(0.15) per share.

CytomX ended 2025 with $137.1 million in cash, cash equivalents and investments, up from $100.6 million, and expects its cash runway to extend to the second quarter of 2027. Clinically, the company announced positive Phase 1 dose-expansion data for Varseta-M in advanced colorectal cancer and is targeting 2026 FDA interactions to align on a potential registrational trial. Combination studies of Varseta-M with bevacizumab and chemotherapy are underway or planned. The CX-801 interferon alpha-2b program in advanced melanoma is advancing through Phase 1, including a combination with KEYTRUDA, with initial combination data expected by the end of 2026.

CytomX Therapeutics reported 2025 results showing a sharp revenue decline alongside progress in its oncology pipeline. Revenue was $76.2 million for 2025, down from $138.1 million in 2024, mainly due to completion and slower recognition of collaboration revenues. Total operating expenses fell to $98.6 million from $113.1 million, but the company moved from net income of $31.9 million in 2024 to a net loss of $17.4 million in 2025, or $(0.15) per share.

CytomX ended 2025 with $137.1 million in cash, cash equivalents and investments, up from $100.6 million, and expects its cash runway to extend to the second quarter of 2027. Clinically, the company announced positive Phase 1 dose-expansion data for Varseta-M in advanced colorectal cancer and is targeting 2026 FDA interactions to align on a potential registrational trial. Combination studies of Varseta-M with bevacizumab and chemotherapy are underway or planned. The CX-801 interferon alpha-2b program in advanced melanoma is advancing through Phase 1, including a combination with KEYTRUDA, with initial combination data expected by the end of 2026.

CytomX Therapeutics reports 2025 collaboration revenue of $76.2 million, down from $138.1 million as several partnered programs advanced or were paused, while expenses fell after a 40% workforce reduction. The company shifted from $31.9 million net income in 2024 to a $17.4 million net loss in 2025.

R&D spending declined to $68.7 million, with investment concentrated in lead programs Varseta-M and CX‑801. Positive Phase 1 data for Varseta-M in late-line metastatic colorectal cancer showed up to 32% confirmed response rate and median progression-free survival of 7.1 months at the 10 mg/kg dose, with largely manageable side effects and an optimized diarrhea prophylaxis regimen.

As of December 31, 2025, CytomX held $137.1 million in cash, cash equivalents and short-term investments, boosted by a May 2025 equity offering and ATM sales. Management expects this to fund operations into the second quarter of 2027 while advancing Varseta-M toward a potential registrational study and progressing CX‑801 and partnered masked-biologic programs.

CytomX Therapeutics reports 2025 collaboration revenue of $76.2 million, down from $138.1 million as several partnered programs advanced or were paused, while expenses fell after a 40% workforce reduction. The company shifted from $31.9 million net income in 2024 to a $17.4 million net loss in 2025.

R&D spending declined to $68.7 million, with investment concentrated in lead programs Varseta-M and CX‑801. Positive Phase 1 data for Varseta-M in late-line metastatic colorectal cancer showed up to 32% confirmed response rate and median progression-free survival of 7.1 months at the 10 mg/kg dose, with largely manageable side effects and an optimized diarrhea prophylaxis regimen.

As of December 31, 2025, CytomX held $137.1 million in cash, cash equivalents and short-term investments, boosted by a May 2025 equity offering and ATM sales. Management expects this to fund operations into the second quarter of 2027 while advancing Varseta-M toward a potential registrational study and progressing CX‑801 and partnered masked-biologic programs.

CytomX Therapeutics reports 2025 collaboration revenue of $76.2 million, down from $138.1 million as several partnered programs advanced or were paused, while expenses fell after a 40% workforce reduction. The company shifted from $31.9 million net income in 2024 to a $17.4 million net loss in 2025.

R&D spending declined to $68.7 million, with investment concentrated in lead programs Varseta-M and CX‑801. Positive Phase 1 data for Varseta-M in late-line metastatic colorectal cancer showed up to 32% confirmed response rate and median progression-free survival of 7.1 months at the 10 mg/kg dose, with largely manageable side effects and an optimized diarrhea prophylaxis regimen.

As of December 31, 2025, CytomX held $137.1 million in cash, cash equivalents and short-term investments, boosted by a May 2025 equity offering and ATM sales. Management expects this to fund operations into the second quarter of 2027 while advancing Varseta-M toward a potential registrational study and progressing CX‑801 and partnered masked-biologic programs.

CytomX Therapeutics: Kynam Capital Management, LP, Kynam Capital Management GP, LLC and Yue Tang report beneficial ownership of 8,966,077 shares of common stock, equal to 5.29% as of 12/31/2025.

The filing states the holders have shared voting and shared dispositive power over those 8,966,077 shares and lists Delaware and United States citizenships for the reporting entities and person.

OrbiMed Advisors LLC reports beneficial ownership of 3,525,650 shares of CytomX Therapeutics, Inc. common stock, representing 2.1% of the class as of 12/31/2025. OrbiMed has shared voting and dispositive power over these shares, which it holds on behalf of other persons entitled to dividends and sale proceeds.

The filing notes this is ownership of 5 percent or less of CytomX’s common stock. OrbiMed states the securities are not held for the purpose of changing or influencing control of CytomX, and its management committee members each disclaim beneficial ownership of the reported shares.

CytomX Therapeutics, Inc. received an amended Schedule 13G filing showing that Tang Capital Management, Kevin Tang, and related Tang Capital entities now report 0 shares of CytomX common stock beneficially owned, representing 0% of the class as of 12/31/2025.

The amendment, identified as Amendment No. 6, confirms that these reporting persons no longer hold voting or dispositive power over any CytomX shares and state that their holdings are 5 percent or less of the outstanding common stock. The filing also certifies that the securities were not acquired or held for the purpose of changing or influencing control of CytomX.

FMR LLC and Abigail P. Johnson report beneficial ownership of 24,688,109 shares of CytomX Therapeutics, Inc. common stock, representing 14.6% of the class as of 12/31/2025, in this Amendment No. 3 to their Schedule 13G.

The shares are reported as held in the ordinary course of business and not for the purpose of changing or influencing control of CytomX. One or more other persons may receive dividends or sale proceeds from these shares, but no such person holds more than five percent of the outstanding common stock.

CytomX Therapeutics granted equity awards to its Chief Business Officer, Rachael Lester, effective February 2, 2026. The filing shows an award of 20,000 shares of common stock, which the footnotes explain are restricted stock units (RSUs) that convert into one share each as they vest. One-third of these RSUs vest annually on March 15, starting in 2027, as long as she continues as a service provider.

The company also granted a stock option for 50,000 shares at an exercise price of $6.09 per share. This option vests in equal monthly installments over four years from February 2, 2026, becoming fully vested on the fourth anniversary if her service continues. In addition, she received 50,000 Performance Stock Units (PSUs), each representing a right to one share of common stock. One-third of the PSUs vest upon the achievement of each of three clinical milestones, again conditioned on continued service.

CytomX Therapeutics Chief Medical Officer Yu-Waye Chu reported new equity awards. On February 2, 2026, Chu received 75,000 shares of Common Stock in the form of restricted stock units at a price of $0 per share. These RSUs convert into one share of Common Stock per unit, with one-third vesting each year on March 15, starting on March 15, 2027, subject to continued service.

On the same date, Chu was granted a stock option for 300,000 shares of Common Stock at an exercise price of $6.09 per share. One forty-eighth of the option vests monthly starting from February 2, 2026, becoming fully vested on the fourth anniversary of that date, also subject to continued service. After these transactions, Chu beneficially owns 210,725 shares of Common Stock, including 206,000 RSUs.

CytomX Therapeutics reported new equity awards for SVP and Chief Scientific Officer Marcia Belvin. On February 2, 2026 she received 60,000 restricted stock units of common stock at a price of $0, increasing her directly held common stock to 332,252 shares, including 218,958 RSUs.

She was also granted a stock option for 250,000 shares of common stock with a $6.09 exercise price. The option vests in equal monthly installments over four years starting from February 2, 2026, and the RSUs vest in three equal annual installments beginning March 15, 2027, subject to continued service.

CytomX Therapeutics reported new equity awards for its Chief Financial Officer, Christopher Ogden. On February 2, 2026, he acquired a stock option covering 325,000 shares of common stock at an exercise price of $6.09 per share and a grant of 90,000 restricted stock units (RSUs) at no cost.

The option vests in equal monthly installments over four years starting from February 2, 2026, becoming fully vested on the fourth anniversary, subject to continued service. The RSUs vest in three equal annual installments each March 15, beginning March 15, 2027, also subject to his continued service.